The effect of human eosinophil major basic protein (MBP) 
Introduction
The lungs contain multiple subtypes of muscarinic receptors ( 1, 2) . Acetylcholine release from the pulmonary parasympathetic nerves stimulates muscannic M3 receptors on smooth muscle, contracting the muscles and causing bronchoconstriction (3) . At the same time, release of acetylcholine from the parasympathetic nerves is limited by inhibitory muscarinic M2 receptors on the nerve endings ( Fig. 1) (4) . Such inhibitory neuronal receptors have been demonstrated in guinea pigs (4) , cats (5), dogs (6) , and humans (7) .
Blocking the neuronal M2 muscarinic receptor using selective antagonists eliminates the normal negative feedback and increases the release of acetylcholine. This results in an 8-10-fold increase in the bronchoconstriction caused by electrical stimulation of the vagus nerves (4) . Conversely, when pilocarpine is used to stimulate the M2 receptors, the response to subsequent vagal stimulation is reduced by 80% (4) .
Inhibitory M2 receptors do not function normally in the airways of asthmatics (8, 9) or in antigen-challenged guinea pigs (10, 11 ) . Loss of negative feedback in these conditions is probably an important cause of increased vagally mediated bronchoconstriction.
In asthmatics (12) (13) (14) (15) and after antigen challenge ( 16, 17) , the airways are infiltrated with eosinophils, which contain three strongly positively charged proteins: major basic protein (MBP; i pI = 10.9), eosinophil peroxidase (EPO; pI = 10.8), and eosinophil cationic protein (ECP; pI = 10.8), as well as the less strongly charged eosinophil-derived neurotoxin (pI = 8.9) ( 18, 19) . Recent studies have shown that several positively charged proteins, including protamine, poly-l-arginine, and poly-l-lysine, are M2 receptor antagonists (20) . Therefore, it is possible that in the face of eosinophilic infiltration of the airways, one or more of these positively charged proteins acts as an endogenous antagonist at the M2 receptor, thereby eliminating the negative feedback control of acetylcholine release and potentiating vagally mediated bronchoconstriction.
We have recently shown that the strongly negatively charged substances hepann and poly-l-glutamic acid both restore the function of M2 receptors in vivo in antigen-challenged guinea pigs ( 11). This effect may result from binding positively charged proteins such as MBP, EPO, or ECP, and displacing them from the neuronal M2 receptors. In this study, we used in vitro ligand-receptor binding studies to further investigate the role ofhuman MBP (and other human eosinophil proteins) in the loss of muscarinic M2 receptor function.
The multiple muscarinic receptor subtypes present in the lung ( 1, 2, 21 ) would make it difficult to use lung membranes to determine the selective effects of these proteins. Therefore, we used guinea pig heart membranes, which contain a homogeneous population of M2 muscarinic receptors (22, 23) , and guinea pig submandibular gland membranes, which contain a homogeneous population of M3 muscarinic receptors (21, 24, 25 
Methods
Tissue preparation. Guinea pigs (Dunkin-Hartley, 250-400 g; Charles River Breeding Laboratories, Wilmington, MA) were killed by asphyxiation with CO2. The heart and parotid glands were quickly removed and rinsed with 50 mM Na+/K' phosphate buffer, pH 7.4. The tissues were blotted dry, weighed, and homogenized using a Polytron (setting 7, 30s; Brinkmann Instruments, Inc., Westbury, NY). Homogenates were centrifuged for 10 min at 1,000 g at4VC, and the supernatants were then centrifuged for 30 min at 30,000 g at4VC. The final pellet was suspended in buffer to give whole organ weight/buffer volume working solutions of 14%. Tissue homogenates were stored in aliquots at -800C. Protein concentrations ofthe homogenates were determined with the Bio-Rad Protein Assay Kit (Bio-Rad Laboratories, Richmond, CA), using bovine serum albumin as a standard.
Isolation ofhuman eosinophil granule proteins. Eosinophil proteins were isolated as described previously (18, 26, 27) . Briefly, granules isolated from human eosinophils were dissolved in 10 mM hydrochloric acid, and the proteins were separated by Sephadex G-50 gel filtration to yield MBP, followed by heparin-Sepharose chromatography to yield ECP and eosinophil-derived neurotoxin, and by carboxymethylSepharose chromatography to yield EPO.
Receptor binding assays. Competition binding experiments were done by incubating guinea pig heart and submandibular gland mem- Nonspecific binding (measured in the presence of atropine (2 x 10-6 M) was subtracted from total binding to determine specific binding. Samples were incubated at room temperature for 3 h, after which unbound ligand was removed by filtration using a Skatron cell harvester. Filters were dissolved in Biosafe II scintillation fluid (Research Products International, Mount Prospect, IL) and counted on a scintillation counter (Beckmann Instruments, Inc., Fullerton, CA).
The dissociation constant (Kd) for [3H]NMS binding to M2 receptors was required for calculation of the Kd for MBP from the competition experiments described above. To determine the Kd for [3H] NMS, heart membranes were incubated to equilibrium with [3H]NMS (0.1, 0.2, 0.4, 0.6, and 1.0 x 10-' M) in the absence (total binding) or presence (nonspecific binding) of atropine (2 X 10-6 M). Samples were handled as above, and the nonspecific binding (which did not exceed 10% of total binding) was subtracted from the total binding to yield specific binding. Data were analyzed using a Scatchard plot, in which the ratio of specifically bound ligand to free ligand is plotted against specifically bound ligand. This yields a linear relationship in which the slope of the regression line is equal to -1 /Kd (28) .
To determine the Kd for MBP, the concentration of MBP required to displace 50% of specifically bound [3H] NMS from guinea pig heart membranes (ED50) was estimated in each of the competition binding experiments. The Kd for MBP binding to the M2 receptor was then determined using the equation (28) (Fig. 7) , demonstrating that EPO, too, is an allosteric antagonist at the M2 receptor.
In contrast, despite being positively charged, ECP at con- centrations as high as 3 X 10-5 M did not displace [3H]NMS from heart membranes ( Fig. 8) . Eosinophil-derived neurotoxin, which is less strongly cationic, had no effect on
[3H]NMS binding to heart membranes at concentrations as high as 1.5 X 10-5 M (the highest concentration tested; data not shown).
The binding ofMBP to M2 receptors was completely reversible by treatment with heparin (Fig. 9) . In these experiments, incubation of [3H]NMS with heart membranes for 6 h in the presence of MBP (l0-5 M) resulted in specific binding of 58±4.3% control. When heparin ( 100 U/ml) was added for the final 3 h of this incubation, the binding of [3H]NMS was restored to 105.3±8.9% control. In control experiments without MBP, [3H]NMS binding to M2 receptors was within 20% of control throughout the range of heparin concentrations tested (0.025-100 U/ml), and was 85% of control at 100 U/ml. ing of [3H]NMS to submandibular gland membranes (M3 receptors). As both MBP and EPO are strongly positively charged, this is consistent with the recent demonstration that the cationic peptides poly-l-arginine, poly-l-lysine, basic histone, and protamine are all antagonists for M2 receptors with no effect on M3 receptors (20) .
The ability of both proteins to slow the dissociation of [3H ]NMS from M2 receptors in the presence ofatropine (Figs. 4 and 7) demonstrates that they are allosteric antagonists. This is again consistent with the findings of Hu et al., who showed that the interaction of the cationic peptides poly-l-arginine, poly-l-lysine, basic histone, and protamine with the M2 receptor is allosteric (20) . The [3H]NMS remaining bound after a 5-min incubation with MBP ( 10-5 and 3 x 10-5 M) and atropine was actually greater than that bound in the absence of atropine. This phenomenon, which has been described with other allosteric antagonists (29) (30) (31) , is not understood.
In addition to positive charge, there must be other structural characteristics that determine whether a protein will act as an M2 receptor antagonist. Despite its strong positive charge, ECP did not displace [3H]NMS from heart membranes. This is again consistent with the studies of Hu et al. (20) , who showed that despite their positive charge, putrescine and spermidine were not M2 receptor antagonists.
It has recently been shown that aspartate residues that are conserved in all muscarinic receptor subtypes, at positions 71 and 99 of the rat Ml receptor, affect the interaction of gallamine, an allosteric antagonist, with the receptor (33) . Mutating these aspartate residues to asparagine altered the affinity of gallamine for the receptor and decreased the maximal effect of gallamine on the binding of [3H]NMS to the receptor. It has been suggested that gallamine's three quaternary amine groups allow it to interact with these negatively charged aspartate residues. Similar interactions may be involved in the interaction of MBP and EPO with the M2 receptor, as not all such proteins in our study or in the study of Hu et al. (20) were M2 receptor antagonists. It is not possible on the basis of these data to exclude the possibility that MBP and EPO interact with a receptor-linked G protein. Indeed, it has been reported that guanosine-5'-triphosphate and 5'-guanylylimidodiphosphate both increase muscarinic receptor high-affinity binding of the antagonist ligand quinuclidinyl benzilate (34) . It is possible that MBP and EPO decrease antagonist ligand binding by interfering with the interaction of endogenous guanosine-5'-triphosphate and G proteins with the receptor. Whether such interactions would explain the inhibition ofatropine-induced receptor-ligand dissociation is unknown.
Guinea pigs that are sensitized to ovalbumin and then challenged with an aerosol of ovalbumin become hyperresponsive to electrical stimulation of the vagus (10, 35) . This hyperresponsiveness is accompanied by, and probably due to, severe dysfunction of inhibitory M2 receptors on the nerves ( 10) .
Because antigen challenge causes pulmonary eosinophilia ( 16, 17), we postulated that MBP, or one of the other positively charged eosinophil proteins, might be responsible for the M2 receptor dysfunction ( 11) . Consistent with this hypothesis is our finding that intravenous heparin or poly-l-glutamate, both ofwhich bind and neutralize MBP (32, 36) , acutely restore the function of the pulmonary vagal M2 receptor in antigen-challenged guinea pigs ( 11 ) . This recovery ofM2 receptor function causes a 50% decrease in the bronchoconstrictor response to vagal stimulation within 20 min after administration of heparin or poly-l-glutamate. In contrast, neither heparin nor poly-/-glutamate affects the response to vagal stimulation in nonchallenged control guinea pigs. Thus the effect of MBP on M2 receptors may be physiologically relevant in the lungs.
This polyanion induced recovery of M2 receptor function is also reflected in the bronchoconstrictor response to vagal stimulation after treatment with muscarinic agonists and antagonists. In normal guinea pigs, stimulating M2 receptors with pilocarpine suppresses the bronchoconstrictor response to vagal stimulation. Conversely, blocking the M2 receptor with gallamine increases the bronchoconstrictor response to vagal stimulation. In contrast, the effects of both pilocarpine and gallamine on the response to vagal stimulation are markedly reduced in antigen-challenged guinea pigs. Treatment with heparin or poly-l-glutamate completely restores the effects of pilocarpine and gallamine, indicating return of M2 receptor function to normal ( 11) .
Our finding in this study that MBP is a selective allosteric antagonist at the M2 receptor, and that binding of MBP to the M2 receptor can be reversed by heparin, is consistent with MBP being responsible for the loss of M2 receptor function in antigen-challenged guinea pigs. MBP might also be responsible for the M2 receptor dysfunction found in asthmatics (8, 9) , as the airways of asthmatics are also infiltrated with eosinophils (12) (13) (14) (15) . As MBP is a selective M2 antagonist, it will increase acetylcholine release from pulmonary vagal fibers without blocking the M3 receptors that mediate the smooth muscle response to acetylcholine.
On a molar basis EPO, which is also cationic, is only slightly less potent than MBP as an M2 antagonist. However, EPO is present in much smaller molar amounts in the eosinophil granule than is MBP (Gleich, G. J., unpublished observations). Considering that EPO is less plentiful than MBP, and that it is also less potent as an M2 antagonist, the effects of EPO on M2 receptors may not be physiologically relevant.
While the actual concentration of MBP in the tissues is not known, the finding of micromolar amounts of MBP in the sputum of patients with acute asthma (37) suggests that tissue concentrations (which would probably be higher than sputum concentrations) are in the range that we have shown affects the M2 receptor. Thus, the ability of MBP to act as an endogenous antagonist of inhibitory muscarinic M2 receptors may be important in explaining the increased vagally mediated bronchoconstriction characteristic of asthma.
